Bausch + Lomb names global president, pharmaceuticals

Daniel Wechsler joins from Merck & Co

Bausch + Lomb, the New York-headquartered global eye health company, has appointed Daniel Wechsler as corporate vice president and global president of its pharmaceuticals business.

Wechsler was most recently head of US strategy, commercial model innovation and business development for Merck & Co, a role to which he was appointed following the company's acquisition of Schering-Plough in 2009.

From 2005 to 2009, Wechsler was group vice president, global business operations and selling excellence, for Schering-Plough, and a member of the global management team. As part of this role, Wechsler led the human health business integration following the company's acquisition of Organon. Prior to this, Wechsler was vice president of US specialist sales at Pfizer.

Wechsler takes over responsibility for Bausch + Lomb’s Pharmaceuticals business from Brent Saunders, who has been acting as interim global president of the business unit for the past few months.

Bausch + Lomb is a global leader in contact lenses and lens care products, ophthalmic surgical devices and instruments, and ophthalmic pharmaceuticals. Its pharmaceuticals portfolio includes prescription and over-the-counter products to treat infection, inflammation, and allergy, as well as eye nutrition.

You may also like

Finance

Valeant Pharmaceuticals to acquire Synergetics USA

Acquisition will further enhance Bausch + Lomb's presence around the world in the rapidly evolving field of vitreoretinal surgery
Finance

Valeant to purchase Bausch + Lomb for US$8.7bn

Will establish Valeant as a global leader in eye health and dermatology
Finance

Bausch + Lomb to purchase ISTA Pharmaceuticals for US$500m

Adds anti-inflammatory, allergy and glaucoma products to portfolio
Finance

Bausch + Lomb launches pharmaceuticals business in India

Partnership with Micro Labs will provide high quality manufacturing capabilities
You need to be a subscriber to read this article.
Click here to find out more.
Finance

Britain's biotech potential (part II): world-class science, second-class support?

In part one, Manufacturing Chemist explored the UK’s world-class science base and early-stage investment appeal. In this second instalment, attention turns to the structural gaps that are limiting its ability to scale
Finance

Sun Pharma to acquire Organon in $11.75bn deal, expanding global manufacturing and biosimilars reach

The firm will acquire Organon in an all-cash $11.75bn transaction, creating a larger global pharma group with expanded manufacturing capacity, stronger women's health operations and a top-10 biosimilars position
Finance

UK biotech venture capital rises 17% in Q1 2026 as deal activity surges 67% year-on-year, BIA figures show

Total UK biotech equity financing reached £552m in the first quarter of 2026, driven by a 17% quarterly rise in venture capital investment, according to BioIndustry Association data, though public markets remain dormant with no IPOs recorded since 2022
Subscribe now